Summary
This trial is testing two new targeted radioactive treatments, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced cancers that have a protein called Gastrin-Releasing Peptide Receptor (GRPR) on their cancer cells.
The treatments are designed to attach to GRPR-positive cancer cells and deliver radiation directly to the tumour. Researchers want to find out how safe these treatments are, what side effects they may cause, how the treatments move through the body, and whether they can help control cancer growth.
Who can take part?
You may be eligible for this study if:
- you have a solid cancer that:
- has spread to other parts of the body (metastatic), or
- has grown locally and cannot be removed with surgery (locally advanced or unresectable)
- your cancer has a protein called Gastrin-Releasing Peptide Receptor (GRPR)
- your cancer has progressed despite treatment, you were unable to tolerate treatment, or you are not eligible for standard treatment options
The study has two parts.
Phase 1
Researchers will test different dose levels of the study treatments to find the safest dose, better understand side effects, measure how the treatment is taken up by tumours and normal organs, and identify the recommended dose for future studies.
Phase 1b
Once the recommended dose has been identified, more participants will receive the treatment. This part of the study will focus on people with HR+/HER2-negative breast cancer, prostate cancer and colorectal cancer, while also including people with other GRPR-positive solid tumours.